Article
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.
Oncotarget - 21 Feb 2017
Del Re Marzia, Tiseo Marcello, Bordi Paola, D'Incecco Armida, Camerini Andrea, Petrini Iacopo, Lucchesi Maurizio, Inno Alessandro, Spada Daniele, Vasile Enrico, Citi Valentina, Malpeli Giorgio, Testa Enrica, Gori Stefania, Falcone Alfredo, Amoroso Domenico, Chella Antonio, Cappuzzo Federico, Ardizzoni Andrea, Scarpa Aldo, Danesi Romano
Abstract excerpt
INTRODUCTION: KRAS oncogene mutations (MUTKRAS) drive resistance to EGFR inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) depends on activating EGFR mutations (MUTEGFR). However, inhibition of EGFR may select resistant cells displaying alternative signaling, i.e.,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.